Regenxbio (RGNX) Liabilities and Shareholders Equity (2014 - 2025)

Regenxbio's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $453.0 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.78% year-over-year to $453.0 million in Q4 2025; TTM through Dec 2025 was $2.1 billion, a 6.11% decrease from a year earlier, with the FY2025 full-year figure at $453.0 million, down 2.78% from the prior year.
• Liabilities and Shareholders Equity eased to $453.0 million in Q4 2025 per RGNX's latest filing, from $525.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2021 and bottomed at $453.0 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $658.1 million (2023), against an average of $709.9 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 89.56% in 2021 and sank 31.12% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then declined by 25.19% to $833.3 million in 2022, then plunged by 31.12% to $574.0 million in 2023, then declined by 18.81% to $466.0 million in 2024, then retreated by 2.78% to $453.0 million in 2025.
• Per Business Quant, the three latest RGNX Liabilities and Shareholders Equity figures stand at $453.0 million (Q4 2025), $525.2 million (Q3 2025), and $581.0 million (Q2 2025).